Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Shukra Pharmaceuticals Ltd (SHUKRAPHAR)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524632 NSE: SHUKRAPHAR Pharmaceuticals & Drugs | Small Cap | Shukra Pharmaceut. Share Price
₹61.84 -0.20 (-0.32%)
As on 01-Oct'26 16:59
Shukra Pharmaceuticals Ltd (SHUKRAPHAR)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524632 NSE: SHUKRAPHAR Pharmaceuticals & Drugs | Small Cap | Shukra Pharmaceut. Share Price
₹61.84 -0.20 (-0.32%)
As on 01-Oct'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹2,726 Cr.
Current Price
₹61.8
52-Week Low / High
₹26 / 65
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
53.6
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
74.01%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
50.96%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹44.1 Cr.
Face Value
₹1
All Time Low / High
₹0.00 / 65.26
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Shukra Pharmaceuticals Ltd a good quality company?
Shukra Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Shukra Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Shukra Pharmaceuticals Ltd vs industry peers?
Shukra Pharmaceuticals Ltd revenue CAGR is %, compared to the industry median CAGR of 0.00%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Shukra Pharmaceuticals Ltd?
Promoters hold 50.96% of the Shukra Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Shukra Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 71.6% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Shukra Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 7.4% | 5.9% | 3.6% | 0.8% | 0.5% | 5.8% | 18.9% | 44.2% | 21.8% | 37% | - |
| Value Creation Index ⓘ | -0.5 | -0.6 | -0.7 | -1.0 | -1.0 | -0.6 | 0.4 | 2.2 | 0.6 | NA | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 5.1 | 5.3 | 5.7 | 11.9 | 11.2 | 20.5 | 58.8 | 74.6 | 32.6 | 56.7 | 75 |
| Sales YoY Gr. | - | 3.9% | 6% | 109.4% | -5.5% | 83% | 187.1% | 26.8% | -56.3% | 74% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | -0 | 0 | 0 | 0.1 | 0.4 | 0.2 | 0.5 | 0.8 |
| YoY Gr. | - | 0% | 0% | -100% | NA | NA | 400% | 320% | -47.6% | 127.3% | - |
| BVPS (₹) ⓘ | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 1.6 | 1.3 | 1.4 | 1.9 | 2.5 |
| Adj Net Profit ⓘ | 0.5 | 0.5 | 0.5 | -0 | 0.1 | 0.8 | 4.4 | 18.5 | 9.6 | 22 | 36 |
| Cash Flow from Ops. ⓘ | -0.3 | 0.8 | 0.3 | 1.2 | 0.5 | 8 | 3.2 | -5.2 | 7.9 | 3.2 | - |
| Debt/CF from Ops. ⓘ | -0.1 | 4.3 | 23.4 | 6.5 | 18.2 | 0.4 | 1.6 | -0.6 | 0.5 | 1.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 30.6% | 38.3% | -1.2% | 74% | ||||
| Adj EPS ⓘ | 43% | NA | 71% | 127.3% | ||||
| BVPSⓘ | 16.7% | 30% | 6% | 34% | ||||
| Share Price | 71.6% | 176.9% | 154.8% | 79.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 3.5 | 3.6 | 3 | -0.2 | 0.9 | 4.7 | 21.2 | 44.7 | 15.9 | 28.8 | 37.1 |
| Op. Profit Mgn % ⓘ | 28.5 | 30.2 | 29.1 | 13 | 12.9 | 14.1 | 9.1 | 26 | 39.1 | 50.8 | 65 |
| Net Profit Mgn % ⓘ | 9.8 | 9.9 | 8.2 | -0.3 | 1.2 | 3.7 | 7.5 | 24.9 | 29.4 | 38.8 | 48.3 |
| Debt to Equity ⓘ | 0 | 0.2 | 0.4 | 0.5 | 0.6 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 379 | 467 | 526 | 334 | 487 | 277 | 201 | 233 | 558 | 422 | 553 |
| Cash Conv. Cycle ⓘ | 64 | 31 | 40 | 39 | 132 | 54 | -9 | 10 | 111 | 61 | 404 |
Valuation of Shukra Pharmaceut. - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Shukra Pharmaceuticals Ltd FAQs
The current trading price of Shukra Pharmaceut. on 01-Oct-2026 16:59 is ₹61.84.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 30-Sep-2026 the market cap of Shukra Pharmaceut. stood at ₹2,725.8 Cr
The latest P/E ratio of Shukra Pharmaceut. as of 30-Sep-2026 is 75.62.
The latest P/B ratio of Shukra Pharmaceut. as of 30-Sep-2026 is 24.82.
The 52-week high of Shukra Pharmaceut. is ₹65.40 and the 52-week low is ₹26.30.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Shukra Pharmaceut. is ₹74.84 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Shukra Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Shukra Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Shukra Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals is an ambitious organisation with a deep rooted focus on sustainability with its impressive range of solutions. The company is committed to deliver excellence across National & Global markets. It is a public limited organisation with globally acclaimed manufacturing facilities.
The company is strongly committed to its values that guide it - The Shukra Group in serving the needs of its stakeholders including customers, suppliers, employees and other interest groups by large. Shukra stands for uncompromising quality and efficiency to deliver proven solutions delivered by passionate and motivated team of individuals.
The company boasts fully integrated structure for manufacturing general formulations like Tablet, Capsules and small volume parenteral since 2017. Along with internationally accredited facilities it invests in people.
The company has embarked upon its ambitious journey in the field of Pharamaceutical (date of inception) with a fully integrated plant in Rakanpor in Kalol, Gandhinagar - Gujarat. Since then, there was no looking back, within a short span of (years) the company has come a long way in making its mark in the sector.
The company has now developed an internationally accredited Laboratory in Ahmedabad where each product and solutions are developed under stringent quality processes.
Business area of the company
The company is engaged in the business of manufacturing and trading of pharmaceuticals Products, laboratory testing.
You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
